Cartesian Therapeutics, Inc.
RNAC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $464 | $102 | $136 | $311 |
| - Cash | $213 | $77 | $106 | $114 |
| + Debt | $14 | $11 | $38 | $35 |
| Enterprise Value | $265 | $36 | $68 | $232 |
| Revenue | $39 | $26 | $111 | $85 |
| % Growth | 49.6% | -76.5% | 30.2% | – |
| Gross Profit | $39 | $26 | $109 | $85 |
| % Margin | 100% | 100% | 98.2% | 100% |
| EBITDA | -$76 | -$235 | $40 | -$5 |
| % Margin | -195.3% | -903.8% | 36% | -6.1% |
| Net Income | -$77 | -$220 | $35 | -$26 |
| % Margin | -199% | -844.9% | 31.9% | -30.2% |
| EPS Diluted | -3.29 | -49.76 | 3 | -6.6 |
| % Growth | 93.4% | -1,758.7% | 145.5% | – |
| Operating Cash Flow | -$24 | -$51 | -$32 | -$60 |
| Capital Expenditures | -$9 | -$0 | -$1 | -$1 |
| Free Cash Flow | -$33 | -$51 | -$33 | -$61 |